TILS.L Regulatory News (TILS)

25 Mar 2008 15:12

ReGen Therapeutics PLC25 March 2008 For Immediate Release 25/03/2008 ReGen's ColostrininTM First European Approval for Sale in Cyprus by GolgiPharmaceuticals Ltd ReGen Therapeutics Plc ('ReGen' or the 'Company', AIM: RGT) is pleased toannounce that the Ministry of Health of the Republic of Cyprus has approved theimportation and sale of its nutritional supplement ColostrininTM by its Cypriotlicensee Golgi Pharmaceuticals Ltd .* To date ColostrininTM is marketed in the US, Canada and Australia under thebrand name CogniSureTM as a nutritional supplement to 'support healthy brainaging and cognition in humans'**. Commenting on this, the first approval to sell ColostrininTM in a territory ofthe European Union, Percy Lomax, Chairman and Chief Executive Officer of ReGensaid: "Cyprus is a member of the European Union which, with the US and Japan, is oneof the three key target areas for ColostrininTM. ReGen will now be working withGolgi to launch the product in Cyprus as soon as possible. Currently, we believea launch date towards the end of the 2nd quarter is possible." * Golgi Pharmaceuticals Ltd is a distributor of pharmaceuticals andnutraceuticals in the Republic of Cyprus. (email address of GolgiPharmaceuticals Ltd - golgipha@cytanet.com.cy) **ColostrininTM for use as a human nutraceutical is licensed in North Americaand Australasia to Metagenics Inc. of San Clemente, California(www.Metagenics.com). Discussions are ongoing with potential distributors inother regions of the world. For further information: Percy LomaxReGen Therapeutics PlcTel No 020 7153 4920 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel No 020 7628 3396 This information is provided by RNS The company news service from the London Stock Exchange